Skip to main content
XOMA
NASDAQ Life Sciences

Major Shareholder BVF Converts $20M Preferred Stock to Common, Boosting Stake to 43.3% Ahead of Merger

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$41.64
Mkt Cap
$522.208M
52W Low
$22.29
52W High
$42.81
52W Position info
87% above low
Off High info
2.7% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

XOMA sits 87% above its 52-week low of $22.29.

Summary

Major shareholder Biotechnology Value Fund converted $20.11 million in preferred stock to common shares at $4.03 each, increasing its stake to 43.3% of XOMA Royalty Corp ahead of its pending acquisition.


Key Events · Ownership and Investor Activity · XOMA

  • Strategic Preferred Stock Conversion

    Biotechnology Value Fund (BVF) and its affiliates converted 5,003,000 shares of Series X Preferred Stock into common stock at a conversion price of $4.03 per share, totaling $20.11 million.

  • Significant Increase in Ownership

    This conversion boosts BVF's aggregate beneficial ownership to 7,593,303 common shares, representing 43.3% of XOMA Royalty Corp's outstanding stock.

  • Pre-Merger Positioning

    The conversion occurred on May 14, 2026, shortly after the announcement of XOMA's acquisition by Ligand Pharmaceuticals for $39.00 per share, indicating a strategic move to consolidate voting power.

  • Waiver of Notice Period

    The company waived a 61-day notice requirement, allowing BVF to increase its Series X Beneficial Ownership Limitation to 45% and proceed with the conversion rapidly.


Analysis · XOMA · Life Sciences

Biotechnology Value Fund (BVF) and its affiliates converted $20.11 million worth of Series X Preferred Stock into 5,003,000 common shares at a highly favorable price of $4.03 per share. This strategic move, occurring just before the company's acquisition by Ligand Pharmaceuticals for $39.00 per share, significantly increases BVF's beneficial ownership to 43.3% of XOMA's outstanding common stock. The conversion, which involved waiving a notice period, solidifies BVF's position and voting power, indicating strong conviction in the company's value or the merger's outcome.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XOMA was trading at $41.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $522.2M. The 52-week trading range was $22.29 to $42.81. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XOMA - Latest Insights

XOMA
Jun 12, 2026, 5:24 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $41.79
Real-time Price: $44.60 info
Change: +$2.81 (+7%) info
Market Cap: $710.155M info
XOMA
Jun 12, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $41.79
Real-time Price: $44.60 info
Change: +$2.81 (+7%) info
Market Cap: $710.155M info
XOMA
Jun 12, 2026, 5:22 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $41.79
Real-time Price: $44.60 info
Change: +$2.81 (+7%) info
Market Cap: $710.155M info
XOMA
Jun 10, 2026, 5:19 PM EDT
Filing Type: DEFM14A
Importance Score:
7
Price at Filing: $41.76
Real-time Price: $44.60 info
Change: +$2.84 (+7%) info
Market Cap: $710.155M info
XOMA
May 26, 2026, 11:28 AM EDT
Filing Type: 425
Importance Score:
9
Price at Filing: $41.63
Real-time Price: $44.60 info
Change: +$2.98 (+7%) info
Market Cap: $710.155M info